Accelerate Diagnostics, Inc. (AXDX)
Market Cap | 20.48M |
Revenue (ttm) | 12.06M |
Net Income (ttm) | -61.62M |
Shares Out | 21.66M |
EPS (ttm) | -4.94 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 11,941 |
Open | 0.929 |
Previous Close | 0.931 |
Day's Range | 0.888 - 0.950 |
52-Week Range | 0.730 - 11.900 |
Beta | 0.53 |
Analysts | Hold |
Price Target | 1.00 (+5.26%) |
Earnings Date | May 9, 2024 |
About AXDX
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic sus... [Read more]
Financial Performance
In 2023, AXDX's revenue was $12.06 million, a decrease of -5.43% compared to the previous year's $12.75 million. Losses were -$61.62 million, -1.40% less than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for AXDX stock is "Hold" and the 12-month stock price forecast is $1.0.
News
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results
TUCSON, Ariz. , March 28, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2023.
Accelerate Diagnostics Scheduled Call to Review 2023 Fourth Quarter and Full Year Results.
TUCSON, Ariz. , March 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, March 28, 2024, at 4:30 p.m.
Accelerate Diagnostics Announces Pricing of Approximately $15 Million Public Offering and Private Placement
TUCSON, Ariz. , Jan. 19, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) (the "Company") today announced the pricing of an underwritten public offering consisting of 6,860,659 units, ...
Accelerate Diagnostics Announces Launch of Proposed Public Offering
TUCSON, Ariz. , Jan. 16, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) (the "Company") today announced the launch of a proposed underwritten public offering of 4,500,000 units, each...
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2023 Results
TUCSON, Ariz. , Jan. 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes an...
Accelerate Diagnostics Announces Collaboration for the Use of the Arc™ System in Combination With Bruker´s MALDI Biotyper®
Working together to bring rapid, automated microbial identification directly from positive blood culture samples TUCSON, Ariz. , Nov. 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXD...
Accelerate Diagnostics Reports Third Quarter 2023 Results
TUCSON, Ariz. , Nov. 9, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2023.
Accelerate Diagnostics Scheduled Call to Review 2023 Third Quarter Results.
TUCSON, Ariz. , Oct. 30, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, November 9, 2023, at 4:30 p.m.
Accelerate Diagnostics Reports Second Quarter 2023 Financial Results
TUCSON, Ariz. , Aug. 10, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2023.
Accelerate Diagnostics Scheduled Call to Review 2023 Second Quarter Results
TUCSON, Ariz. , July 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, August 10, 2023, at 4:30 p.m.
Accelerate Diagnostics Announces 1-for-10 Reverse Stock Split
TUCSON, Ariz. , July 10, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc., (NASDAQ: AXDX) (the "Company") a leading provider of innovative rapid diagnostic solutions, announced that it will conduct a...
Accelerate Diagnostics Announces Successful Completion of Debt Restructuring Support Agreement, Supporting Advancement of Next-Generation Platform Wave
TUCSON, Ariz. , June 13, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc., (NASDAQ: AXDX) a leading provider of innovative rapid diagnostic solutions, has closed the transactions contemplated by the ...
Accelerate Diagnostics Reports First Quarter 2023 Financial Results
TUCSON, Ariz. , May 11, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter for the period ended March 31, 2023.
Accelerate Diagnostics scheduled call to review 2023 first quarter results
TUCSON, Ariz. , April 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, May 11, 2023, at 4:30 p.m.
Accelerate Diagnostics Reports Fourth Quarter and Full Year 2022 Financial Results
TUCSON, Ariz. , March 29, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2022.
Accelerate Diagnostics scheduled call to review 2022 fourth quarter and full year results
TUCSON, Ariz. , March 15, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Wednesday, March 29, 2023, at 4:30 p.m.
Accelerate Diagnostics announces departure of CFO Steve Reichling and appointment of David Patience as replacement
TUCSON, Ariz. , March 14, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) a leading provider of innovative rapid diagnostic solutions, announced today that Steve Reichling will be step...
Accelerate Diagnostics announces appointment of Hany Massarany to Chairman of Board of Directors
TUCSON, Ariz. , March 8, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) a disruptor in bloodstream infection identification and susceptibility testing today announced the appointment...
Accelerate Diagnostics submits 510(K) application to FDA for Gram-negative menu expansion and breakpoint updates for the Accelerate PhenoTest® BC kit
TUCSON, Ariz. , Dec. 19, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that the Company has submitted a 510(k) application to the FDA for Gram-negative menu expansio...
Accelerate Diagnostics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Boston, Massachusetts--(Newsfile Corp. - November 15, 2022) - Block & Leviton is investigating Accelerate Diagnostics, Inc. (NASDAQ: AXDX) for potential securities law violations. Investors who have l...
Accelerate Diagnostics Reports Third Quarter 2022 Financial Results
TUCSON, Ariz. , Nov. 14, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter for the period ended September 30, 2022.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Accelerate Diagnostics, Inc. - AXDX
NEW YORK , Nov. 14, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Accelerate Diagnostics, Inc. ("Accelerate" or the "Company") (NASDAQ: AXDX). Such investors ar...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Accelerate Diagnostics, Inc. (AXDX) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Accelerate Diagno...
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Accelerate Diagnostics, Inc. and Encourages Investors with Losses to Contact the Firm
Los Angeles, California--(Newsfile Corp. - October 27, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of A...
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Accelerate Diagnostics, Inc. (AXDX) on Behalf of Investors
BENSALEM, Pa.